Cynosure Enhances Industry-Leading Smartlipo Family with 1440 nm Wavelength
October 22 2009 - 8:30AM
PR Newswire (US)
New Smartlipo Triplex(TM) Laser Lipolysis Workstation Delivers
Higher Absorption of Fatty Tissue with Same Powerful Tissue
Coagulation and Tightening Effect WESTFORD, Mass., Oct. 22
/PRNewswire-FirstCall/ -- Cynosure, Inc. (NASDAQ: CYNO), a leading
developer and manufacturer of a broad array of light-based
aesthetic treatment systems, today announced the introduction of
Smartlipo Triplex(TM), the world's first laser lipolysis solution
featuring three wavelengths that combine to deliver high-powered
fat absorption and tissue tightening through tissue coagulation.
Smartlipo Triplex will be formally launched at Plastic Surgery
2009, the American Society of Plastic Surgeons Annual Meeting,
which will be held October 23-27 in Seattle. Smartlipo Triplex adds
a 1440 nm wavelength to the MPX generation of the product, and
employs Cynosure's patented MultiPlex technology to combine the
benefits of three wavelengths in one laser output. MultiPlex
technology enables two wavelengths to be fired sequentially,
creating a blended thermal and photomechanical effect that
efficiently liquefies fat and tightens skin through collagen
remodeling. "With 20 times greater absorption in fatty tissue than
any other single wavelength on the market, the 1440 nm wavelength
puts Smartlipo in a new class," said Barry DiBernardo, M.D.,
Medical Director of New Jersey Plastic Surgery & MedNet
Technologies, Inc. in Montclair, NJ. "Combining the photomechanical
effects of the 1440 nm with the 1064 nm wavelength results in even
greater disruption of fatty tissue for faster and deeper treatments
than the 1064 wavelength alone. At the same time, the Smartlipo
Triplex continues to deliver unmatched tissue tightening through
tissue coagulation by blending the 1064 and 1320 nm wavelengths."
"We continue to advance our Smartlipo family of products to address
the demands of the marketplace: faster and greater absorption of
fat, high-definition body sculpting capabilities and tissue
tightening through tissue coagulation," said Cynosure President and
Chief Executive Officer Michael Davin. "We believe that Smartlipo
Triplex enables medical professionals to deliver the most accurate
combination therapy available today by providing a superior mix of
energy levels and wavelengths. Whether treating a small
well-defined area or removing larger amounts of fatty tissue,
Smartlipo Triplex offers doctors the ability to customize the
treatment to achieve maximum results. At the same time, we believe
our safety features are unmatched in the industry." Smartlipo
Triplex is equipped with SmartSense with ThermaGuide, the latest in
Cynosure's proprietary family of intelligent energy delivery
systems. SmartSense with ThermaGuide is designed to work in harmony
with the laser. It continually detects the temperature under the
skin and controls the output of energy. This helps to ensure that
the treatment area remains within a safe and optimal temperature
range for fat removal and tissue tightening through tissue
coagulation. "Smartlipo Triplex is the technology of choice for my
body sculpting procedures," said John Millard, M.D., a
board-certified plastic surgeon based in Denver. "It allows for
quick and efficient removal of fat without excess heat - a
requirement for high-definition results." About Cynosure, Inc.
Cynosure, Inc. develops and markets aesthetic treatment systems
that are used by physicians and other practitioners to perform
non-invasive and minimally invasive procedures to remove hair,
treat vascular and pigmented lesions, rejuvenate the skin, liquefy
and remove unwanted fat through laser lipolysis and temporarily
reduce the appearance of cellulite. Cynosure's products include a
broad range of laser and other light-based energy sources,
including Alexandrite, pulse dye, Nd:YAG and diode lasers, as well
as intense pulsed light. Cynosure was founded in 1991. For
corporate or product information, contact Cynosure at 800-886-2966,
or visit http://www.cynosure.com/. Forward-Looking Statements Any
statements in this press release about future expectations, plans
and prospects for Cynosure, Inc., including statements about
expectations for its new Smartlipo Triplex as well as other
statements containing the words "believes," "anticipates," "plans,"
"expects," "will" and similar expressions, constitute
forward-looking statements within the meaning of The Private
Securities Litigation Reform Act of 1995. Actual results may differ
materially from those indicated by such forward-looking statements
as a result of various important factors, including the global
economic recession and its effects on the aesthetic laser industry,
Cynosure's history of operating losses, its reliance on sole source
suppliers, the inability to accurately predict the timing or
outcome of regulatory decisions, changes in consumer preferences,
competition in the aesthetic laser industry, economic, market,
technological and other factors discussed in Cynosure's most recent
Annual Report on Form 10-K and Quarterly Report on Form 10-Q, which
are filed with the Securities and Exchange Commission. In addition,
the forward-looking statements included in this press release
represent Cynosure's views as of the date of this press release.
Cynosure anticipates that subsequent events and developments will
cause its views to change. However, while Cynosure may elect to
update these forward-looking statements at some point in the
future, it specifically disclaims any obligation to do so. These
forward-looking statements should not be relied upon as
representing Cynosure's views as of any date subsequent to the date
of this press release. Contact: Scott Solomon Vice President Sharon
Merrill Associates, Inc. 617-542-5300 DATASOURCE: Cynosure, Inc.
CONTACT: Scott Solomon, Vice President of Sharon Merrill
Associates, Inc., +1-617-542-5300, Web Site:
http://www.cynosure.com/
Copyright